Regeneron Pharmaceuticals Inc. News
Latest updates and market news for REGN
16 news
Nov 24 - Nov 30, 2025
Page 1
Barchart
Is Regeneron Pharmaceuticals Stock Underperforming the S&P 500?
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
The Bull Case For Regeneron (REGN) Could Change Following European Approval of Dupixent for CSU Patients
📊
AI Sentiment
Positive
7/10
Insider Monkey
Deutsche Bank Maintains a Buy Rating on Sanofi (SNY)
📈
AI Sentiment
Highly Positive
8/10
Zacks
Regeneron (REGN) Up 20.2% Since Last Earnings Report: Can It Continue?
📊
AI Sentiment
Positive
7/10
Pharmaceutical Technology
Dupixent gains chronic spontaneous urticaria indication in Europe
📈
AI Sentiment
Highly Positive
8/10
Bloomberg
Hedge Funds Pile Into Health Stocks Leading Market in Rotation
📊
AI Sentiment
Positive
7/10
Simply Wall St.
Regeneron Pharmaceuticals (REGN): Examining Valuation After Recent Share Price Momentum
📊
AI Sentiment
Positive
7/10
Zacks
SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
Regeneron, Sanofi Say EU Approves Dupixent for Inflammatory Skin Disease
➖
AI Sentiment
Neutral
5/10
GlobeNewswire
Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
📈
AI Sentiment
Highly Positive
8/10
Investor's Business Daily
Bristol Myers Pops On A 'Surprisingly Positive' Update From Key Rival Bayer
📈
AI Sentiment
Highly Positive
8/10
Motley Fool
1 Reason Why Shares of Regeneron Pharmaceuticals Are Surging This Month
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
HSBC Initiates Regeneron Pharmaceuticals at Buy With $890 Price Target
📊
AI Sentiment
Positive
7/10
Share this news page